GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Equity-to-Asset

PolyPeptide Group AG (XSWX:PPGN) Equity-to-Asset : 0.55 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PolyPeptide Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF359.5 Mil. PolyPeptide Group AG's Total Assets for the quarter that ended in Dec. 2023 was CHF649.9 Mil. Therefore, PolyPeptide Group AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.55.

The historical rank and industry rank for PolyPeptide Group AG's Equity-to-Asset or its related term are showing as below:

XSWX:PPGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47   Med: 0.54   Max: 0.73
Current: 0.55

During the past 6 years, the highest Equity to Asset Ratio of PolyPeptide Group AG was 0.73. The lowest was 0.47. And the median was 0.54.

XSWX:PPGN's Equity-to-Asset is ranked worse than
53.64% of 1085 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs XSWX:PPGN: 0.55

PolyPeptide Group AG Equity-to-Asset Historical Data

The historical data trend for PolyPeptide Group AG's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Equity-to-Asset Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.49 0.47 0.71 0.73 0.55

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.74 0.73 0.65 0.55

Competitive Comparison of PolyPeptide Group AG's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Equity-to-Asset falls into.



PolyPeptide Group AG Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PolyPeptide Group AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=359.524/649.862
=0.55

PolyPeptide Group AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=359.524/649.862
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (XSWX:PPGN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PolyPeptide Group AG Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines